Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.5, and our video podcast, CANCER BUZZ TV.

Industry News Archive

FDA Approves Expanded Indication for Pembrolizumab for cSCC

On July 6, 2021, the U.S. Food and Drug Administration (FDA) approved an expanded label for pembrolizumab as a monotherapy treatment for patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Read Merck's announcement.

Posted 7/6/2021

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us